About us

Mitochon Technologies was founded in 2018 with the specific purpose of developing new therapies for mitochondrial diseases. The lead molecule of the company’s late-stage portfolio – BGP-15 – was in-licensed from a US based company in 2019. Multiple phase 2 studies are currently being initiated and several preclinical projects are ongoing in various diseases.